From Yahoo Finance: 2025-05-21 11:22:00

Capricor Therapeutics, Inc. (CAPR) is a biotechnology company focusing on cell and exosome-based therapies for diseases like Duchenne muscular dystrophy. With financial strength and innovative science, Capricor is well-positioned for growth and success in the medical field. Wall Street analysts see a 489% upside potential in CAPR over the next year.

Capricor Therapeutics (CAPR) recently announced FDA plans to review its cell therapy for Duchenne muscular dystrophy cardiomyopathy. Despite a 15% drop in stock price, Wall Street analysts recommend CAPR as a “Strong Buy” with a 489.89% upside potential. Financially strong with $78 million in cash reserves, Capricor shows promise in the biotechnology sector.

Capricor Therapeutics, Inc. has reported strong financial results, with revenues of $11.13 million in Q4 2024 and $25.4 million in annual revenue. The company’s strategic collaborations and initiatives, including cell therapy programs, position it for ongoing success in developing innovative treatments for complex medical conditions.

Capricor Therapeutics, Inc. ranks 4th on the list of 13 Best Multibagger Stocks to Invest in Now. While CAPR shows potential, other AI stocks may offer higher returns with limited downside risk. For investors seeking a promising AI stock with 100x upside potential, exploring other options may be beneficial.

Read more: Analysts See 489% Upside Potential